Aspirin and Neutrophils in Preeclampsia

Launched by QUEEN MARY UNIVERSITY OF LONDON · Jul 16, 2021

Keywords

ClinConnect Summary

This clinical trial, called "Aspirin and Neutrophils in Preeclampsia," is studying how low-dose aspirin (a common medication) affects the immune system in pregnant women who are at high risk of developing a condition called preeclampsia. Preeclampsia can cause serious complications during pregnancy, and while aspirin is often used to help prevent it, some women still develop the condition despite taking the medication. The researchers want to understand the differences in immune responses between women who benefit from aspirin and those who do not.

To participate in this study, women must be between 18 and 60 years old, have a single baby (singleton pregnancy), and be currently taking low-dose aspirin as part of their routine care. If eligible, participants will give blood samples at specific times during their pregnancy to help researchers learn more about changes in their immune system. This study is taking place at Barts Health NHS Trust. It's important to know that participants will need to provide informed consent and should be able to understand written English to join the study.

Gender

FEMALE

Eligibility criteria

• • Inclusion criteria
• • Age 18-60 years
• • Singleton pregnancy
• • Live fetus at 11-13 weeks of gestation
• • Informed, written consent
• • Upper age of 60 years
• • Patient taking low dose aspirin as standard of care
• • Exclusion criteria
• • Unwilling or unable to give consent
• • Participants who are unable to understand written English